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Abstract
Objectives: We aimed to identify risk factors for acute pulmonary events in children and adolescents in
the Pulmonary Hypertension and the Hypoxic Response in SCD (PUSH) study. Methods: Patients with
hemoglobin SS (n = 376) and other sickle cell genotypes (n = 127) aged 3–20 yrs were studied at four
centers in a cross-sectional manner. A subgroup (n = 293) was followed for a median of 21 months (range
9–35). Results: A patient-reported history of one or more acute pulmonary events, either acute chest
syndrome (ACS) or pneumonia, was obtained in 195 hemoglobin SS patients (52%) and 51 patients with
other genotypes (40%). By logistic regression, history of acute pulmonary events was independently
associated with patient-reported history of asthma (P < 0.0001), older age (P = 0.001), >3 severe pain
episodes in the preceding 12 months (P = 0.002), higher tricuspid regurgitation velocity (TRV) (P = 0.028),
and higher white blood cell (WBC) count (P = 0.043) among hemoglobin SS patients. History of acute
pulmonary events was associated with >3 severe pain episodes (P = 0.009) among patients with other
genotypes. During follow-up, 43 patients (15%) had at least one new ACS episode including 11 without a
baseline history of acute pulmonary events. History of acute pulmonary events (odds ratio 5.0; P < 0.0001)
and younger age (odds ratio 0.9; P = 0.007) were independently associated with developing a new
episode during follow-up. Conclusions: Asthma history, frequent pain, and higher values for TRV and WBC
count were independently associated with history of acute pulmonary events in hemoglobin SS patients
and frequent pain was associated in those with other genotypes. Measures to reduce pain episodes and
control asthma may help to decrease the incidence of acute pulmonary events in SCD.
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Acute chest syndrome (ACS) is a frequent pulmonary com-
plication of sickle cell disease (SCD) deﬁned as an acute
illness characterized by fever and/or respiratory symptoms
accompanied by a new pulmonary inﬁltrate on a chest X-ray
(1, 2). It is second only to vaso-occlusive crisis (VOC) as a
cause of hospitalization and recurrent episodes may cause
debilitating chronic pulmonary disease (3). It is also a leading
cause of death in SCD, accounting for approximately 25% of
deaths (4, 5). The cause of ACS is known in only about a
third of cases and includes pneumonia, pulmonary infarction,
and fat embolism. Other conditions that can precipitate
ACS include general anesthesia and asthma (2, 6–8). The
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pathogenesis of ACS is complex and is related to pulmonary
vaso-occlusion and ischemia, airway inﬂammation, and endo-
thelial dysfunction (9–11). The risk factors for predicting
ACS are not clearly deﬁned. In an analysis of the Coopera-
tive Study of Sickle Cell Disease data, Castro et al. (2)
described younger age, lower hemoglobin F, less severe
anemia, and a higher steady-state leukocyte count as signiﬁ-
cant risk factors for ACS. In contrast, the only risk factor that
predicted ACS in a Brazilian study reported by Araujo et al.
(12) was a history of previous admission. Historically, half of
all SCD patients had at least one episode of ACS in their life-
time and a subset had multiple events. Half of ACS episodes
developed during hospitalization for another complication of
SCD, most frequently VOC (5). In clinical practice, there is
often overlap between the diagnoses of pneumonia and ACS
in children with SCD. In this study, we report clinical factors
associated with patient-reported history of ACS or pneumo-
nia from analysis of data from a more recent cohort of
children and adolescents with SCD.
Patients and methods
Study design and research participants
The Pulmonary Hypertension and the Hypoxic Response in
SCD (PUSH) study is a prospective, multicenter study
designed to determine the prevalence and risk factors of pul-
monary hypertension in children and adolescents with SCD
and to determine the role of the hypoxic response in its
pathogenesis (13). PUSH enrolled participants with hemo-
globin SS (N = 376) and other sickle cell disease genotypes
(N = 127) 3–20 yrs of age as well as age- and gender-
matched controls without SCD at four centers including
Howard University and Children’s National Medical Center
in Washington, DC, the University of Michigan in Ann
Arbor, Michigan, and the Pulmonary and Vascular Medicine
Branch of the NHLBI, Bethesda, MD. The study protocol
was approved by the institutional review boards of all partic-
ipating institutions. Written informed consent to participate
in the study was obtained from the subjects and/or their
legal guardian. The study was performed in accordance with
the Declaration of Helsinki and is registered with clinicaltri-
al.gov (NCT00495638). The patients were evaluated at
steady state, deﬁned as at least 3 wks after hospitalization
for an acute vaso-occlusive crisis or other complication, with
a detailed history and physical examination, laboratory tests,
an echocardiogram, and pulmonary function tests (children
 7 yrs). The present report includes all of the patients with
sickle cell disease enrolled in the study and the subset that
was evaluated after approximately 2 yrs of follow-up.
Participants were evaluated at enrollment, and a subset was
followed prospectively for the occurrence of outcomes. Sickle
cell disease genotype was conﬁrmed by DNA sequencing,
hemoglobin electrophoresis, and/or high-performance liquid
chromatography. a-thalassemia genotyping was performed by
assessing a3.7 and a4.2 thalassemia alleles. Hemoglobin
concentration, leukocyte, platelet and reticulocyte counts,
serum lactate dehydrogenase (LDH), aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), bilirubin, ferritin,
fetal hemoglobin percentage, and creatinine were measured at
enrollment using standard methodologies. Transthoracic
Doppler echocardiography was performed and used to esti-
mate the systolic pulmonary artery pressure through measure-
ment of the peak tricuspid regurgitation velocity (TRV). Left
ventricular ﬁlling pressures were estimated by calculating the
ratio of the mitral inﬂow E wave to the tissue Doppler E wave
(E/Etdi) (14–16). History of the acute pulmonary events of
ACS or pneumonia was obtained by interviewing parents,
guardians, or patients and by reviewing the medical records
for episodes diagnosed as ACS or pneumonia when available,
but chest X-rays and the accompanying symptoms were not
routinely reviewed. The number of severe VOC crises within
the preceding 12 months was family- reported and included
painful crises that required an emergency department or phy-
sician ofﬁce visit or hospitalization. Histories of hydroxyurea
use and blood transfusions were also obtained at enrollment
and follow-up visits.
Statistical analysis
Continuous variables at recruitment were compared between
patients with and without a history of acute pulmonary
events with the Kruskal–Wallis test, and categorical vari-
ables were compared with the chi-square test. Independent
predictors of history of ACS or pneumonia were assessed by
logistic regression analysis. Variables that had P-value  0.2
in univariate analysis were entered into the ﬁnal model. We
also used logistic regression analysis to assess the predictors
of new ACS during the follow-up period. Final multivariate
models were built by the backward stepwise approach. Anal-
yses were performed in STATA 12.0 (StataCorp, College
Station, TX, USA).
Results
From 2006 to 2010, 503 participants aged 3–20 yrs were
enrolled including 376 with hemoglobin SS and 127 with
other SCD genotypes. We ﬁrst analyzed baseline patient
characteristics according to whether or not participants had a
history of at least one acute pulmonary event as shown in
Table 1. A history of ACS or pneumonia was present in
195 (52%) of hemoglobin SS patients and 51 (40%) of
patients with other SCD genotypes (P = 0.023). Compared
to those without such a history, hemoglobin SS patients with
a history of acute pulmonary events at baseline were older,
had signiﬁcantly more severe pain episodes in the preceding
12 months, had received more blood transfusions, more
often had a history of asthma, and had higher median WBC
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counts, serum ferritin concentrations and TRVs. There was
no signiﬁcant difference in gender, a-thalassemia status,
hydroxyurea use, reticulocyte count, LDH, or mitral valve
E/Etdi. In other SCD genotypes, those with a history of
acute pulmonary events were more often receiving hydroxy-
urea and had a higher frequency of severe pain episodes.
We next examined which baseline variables were indepen-
dently associated with history of acute pulmonary events
using a logistic regression model (Table 2). History of
asthma, older age, number of severe pain episodes in the
previous year, TRV, and WBC count were independently
associated with history of ACS or pneumonia in patients
with hemoglobin SS. Number of severe pain episodes in the
previous year and hydroxyurea therapy had signiﬁcant inde-
pendent associations with a history of these acute pulmonary
events in SCD patients with other genotypes.
It can be difﬁcult to adequately evaluate the inﬂuence of
hydroxyurea treatment on risk factors for acute pulmonary
events in SCD. History of acute chest syndrome is an indi-
cation for hydroxyurea but the treatment, once started for a
different complication such as frequent severe pain episodes,
may in turn prevent the development of acute pulmonary
events. A chronic transfusion program can also complicate
the interpretation of cross-sectional data. We therefore
Table 1 Patient characteristics according to history of acute pulmonary events. Results in median (IQ range) unless otherwise indicated
N
Patients without ACS
or pneumonia history N
Patients with ACS or
pneumonia history P
a. Hb SS
Age (yr) 181 11 (6–16) 195 13 (8–17) 0.0007
Female gender, no (%) 181 84 (46%) 195 97 (50%) 0.5
a-thalassemia
Single deletion, no (%) 169 43 (25%) 178 62 (35%) 0.14
Double deletion, no (%) 5 (3%) 3 (2%)
Hydroxyurea treatment, no (%) 181 74 (41%) 195 87 (45%) 0.5
History of chronic transfusion program, no. (%) 179 31 (17%) 193 34 (18%) 0.9
>3 severe pain episodes past year, no (%) 181 11 (6%) 195 46 (24%) <0.0001
More than 10 blood transfusions, no (%) 178 39 (22%) 192 62 (32%) 0.025
History of asthma, no (%) 181 25 (14%) 195 71 (36%) <0.0001
Hemoglobin (g/L) 174 86 (76–97) 188 87 (79–94) >0.9
Reticulocyte count (9109/L) 166 246 (179–330) 183 265 (191–347) 0.16
WBC (9109/L) 173 10.7 (7.8–13.5) 188 11.4 (9.1–13.8) 0.032
Platelets (9109/L) 173 396 (318–484) 188 399 (333–503) 0.2
LDH (U/L) 158 462 (349–589) 167 438 (331–587) 0.3
Creatinine (lmol/L) 172 35.4 (26.5–44.2) 188 35.4 (26.5–44.2) 0.18
Ferritin (lg/L) 148 169 (79–626) 164 348 (129–1144) 0.001
TRV (m/s) 155 2.3 (2.1–2.4) 179 2.4 (2.2–2.5) 0.015
Mitral valve E/Etdi 167 6.7 (5.7–7.5) 184 6.4 (5.6–7.6) 0.7
b. Other genotypes (hemoglobin SC, n = 88; hemoglobin Sb+-thalassemia,
n = 21, hemoglobin Sb0-thalassemia, n = 12; other, n = 6)
Age (yr) 76 11 (7–15) 51 11 (7–15) 0.4
Female gender, no (%) 76 37 (49%) 51 26 (51%) 0.8
a-thalassemia
Single deletion, no (%) 75 19 (25%) 49 26 (33%) 0.4
Double deletion, no (%) 5 (7%) 1 (2%)
Hydroxyurea treatment, no (%) 76 9 (12%) 51 16 (31%) 0.007
History of chronic transfusion program, no. (%) 75 2 (3%) 51 4 (8%) 0.18
>3 severe pain episodes past yr, no (%) 76 2 (3%) 51 11 (22%) 0.001
More than 10 blood transfusions, no (%) 76 3 (4%) 51 5 (10%) 0.18
History of asthma, no (%) 76 13 (17%) 51 13 (25%) 0.3
Hemoglobin (mg/dL) 75 110 (100–117) 49 109 (100–116) 0.8
Reticulocyte count (9109/L) 73 147 (115–178) 47 140 (120–176) 0.7
WBC (9109/L) 75 7.7 (6.1–10.0) 50 7.3 (5.7–9.5) 0.8
Platelet (9109/L) 75 263 (190–397) 50 285 (193–354) 0.5
LDH (U/L) 72 274 (214–354) 46 284 (232–375) 0.4
Creatinine (lmol/L) 76 44.2 (35.4–61.9) 47 44.2 (35.4–53.0) >0.9
Ferritin (lg/L) 66 105 (54–205) 43 136 (71–375) 0.10
TRV (m/s) 72 2.2 (2.0–2.3) 42 2.1 (2.0–2.4) 0.6
Mitral valve E/Etdi 75 6.1 (5.4–7.0) 46 5.9 (5.3–6.8) 0.4
ACS, acute chest syndrome; LDH, lactate dehydrogenase; TRV, tricuspid regurgitation velocity; WBC, white blood cells.
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examined the logistic regression models presented in Table 2
in patients not receiving hydroxyurea and not on a chronic
transfusion program. Among 136 such hemoglobin SS
patients, 70 had a history of acute pulmonary events; age
(odds ratio 1.13, P = 0.001) and history of asthma (odds
ratio 2.9, P = 0.028) had signiﬁcant associations with this
history while >3 severe pain episodes in the previous year
(odds ratio 2.5, P = 0.16), TRV (odds ratio = 3.0, P = 0.2)
and natural log WBC count (odds ratio 2.2, P = 0.15) had
associations that no longer achieved statistical signiﬁcance.
Among 96 patients with other genotypes not receiving
hydroxyurea and not on a chronic transfusion program, 32
had a history of acute pulmonary events; 100% of six
patients with greater than three severe pain episodes in the
previous year had this history compared to 29% of 90
patients with three or less severe pain episodes (P = 0.001).
Follow-up information was available for 293 participants
(62%), including 214 with hemoglobin SS and 79 with
other SCD genotypes, at a median of 21 months (range of
9–50 months). Forty-six percent had a history of ACS or
pneumonia at baseline and 41% were being treated with
hydroxyurea at baseline. The reasons for participants not
having follow-up included recent hospitalization, failure to
keep an appointment, failure to agree to follow-up, inability
to make contact to schedule the follow-up, or end of grant
funding. The children having follow-up did not differ signif-
icantly from those not having follow-up in terms of baseline
history of asthma, history of severe pain episodes, hemoglo-
bin concentration, and markers of hemolysis. During the
follow-up period, 43 patients (15%) experienced ACS
episodes, including 33 hemoglobin SS patients. Among
patients with a history of acute pulmonary events at
baseline, 25% had a new episode of ACS during follow-up
while among 147 patients with no history of ACS or
pneumonia, 7% had a new episode (P < 0.0001). Among
patients receiving hydroxyurea at baseline, 18% had a new
episode of ACS during follow-up while among patients not
receiving hydroxyurea, 14% had a new episode (P = 0.4).
Among all patients, a prior history of acute pulmonary
events (P < 0.0001) and younger age (P = 0.0007) at base-
line were signiﬁcant predictors of ACS during follow-up,
while baseline chronic transfusion program or hydroxyurea
therapy were not signiﬁcant predictors (Table 3).
Discussion
Understanding the risk factors for developing acute pulmo-
nary events such as ACS in SCD may enable us to alleviate
modiﬁable variables and potentially prevent ACS. In clinical
practice, a distinction between pneumonia and ACS is often
blurred; therefore, we used a broader deﬁnition of history of
acute pulmonary events in the present study. We evaluated
a large cohort of SCD patients at baseline and then re-
evaluated more than half of them after approximately 2 yrs.
In the cross-sectional analysis at baseline, a history of acute
pulmonary events was independently associated with >3
severe pain episodes in the preceding year in hemoglobin
SS patients and in patients with other genotypes. Additional
associations with history of acute pulmonary events were
found for history of asthma, older age, higher steady-state
TRV, and higher WBC count in the hemoglobin SS
patients. During the follow-up period, a baseline history of
acute pulmonary events and younger age independently
predicted new ACS episodes.
Our ﬁnding that coexistent asthma was associated with a
history of acute pulmonary events is similar to previous
reports (17, 18). Some investigators have reported that
asthma is more common among children with SCD than
Table 2 Independent predictors of history of ACS or pneumonia from
multiple logistic regression modeling
OR (95% CI) P-value
a. Hb SS (n = 318)1
History of asthma 3.9 (2.1–7.3) <0.0001
Age (yrs) 1.09 (1.03–1.14) 0.001
>3 severe pain episodes in last year 4.4 (1.9–10.1) 0.002
TRV (m/s) 3.2 (1.1–9.1) 0.028
WBC (natural log) 2.03 (1.02–4.01) 0.043
b. Other genotypes (N = 127)2
>3 severe pain episodes in last year 8.35 (1.72–40.58) 0.009
Hydroxyurea treatment 2.76 (1.06–7.23) 0.038
ACS, acute chest syndrome; LDH, lactate dehydrogenase.
1Variables entered into model: age, a-thalassemia status, number of
blood transfusions, category of severe pain episodes, history of
asthma, reticulocyte number, platelets, WBC count, ferritin, LDH,
TRV. Four outliers were removed.
2Variables entered into model: hydroxyurea treatment, number of
blood transfusions, number of severe pain episodes, ferritin.
Table 3 Independent predictors of ACS during the follow-up (n = 273)
OR (95% CI) P-value
History of ACS or pneumonia
at recruitment
5.0 (2.3–11.0) <0.0001
Age (yrs) 0.91 (0.84–0.97) 0.007
Baseline chronic transfusion
program
1.7 (0.7–4.4) 0.3
Baseline hydroxyurea
treatment
1.4 (0.7–2.9) 0.4
ACS, acute chest syndrome; LDH, lactate dehydrogenase.
Variables entered into model include: genotype, age, gender, hydroxy-
urea treatment, number of blood transfusions, number of severe pain
in last year, history of asthma, history of ACS or pneumonia at recruit-
ment, hemoglobin, MCV, WBC (natural log), platelet (square root),
LDH (natural log), ferritin (natural log), tricuspid regurgitation velocity,
mitral valve E/Etdi. Hydroxyurea treatment and chronic transfusion
program were forced into the model.
Area Under ROC Curve = 0.73, P-value for goodness of fit = 0.8.
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ethnic matched controls (19). In contrast, a history of asthma
is similar in SCD and control children in the PUSH study
(13), and a recent review of a number of studies concluded
that the prevalence of asthma in SCD is similar to or slightly
higher than the general African–American population (20).
However, bronchial hyper-responsiveness is more common
in children with SCD than in ethnically matched controls,
and atopic asthma appears to be associated with recurrent
ACS (21, 22). Further research is needed to determine if
aggressive control of asthma may decrease the risk of ACS
in SCD patients.
Our ﬁnding that a history of >3 severe pain episodes in
the preceding 12 months was associated with a history of
acute pulmonary events is consistent with the clinical
observation that severe painful crises often precede ACS.
The mechanism may involve the development of hypoven-
tilation and atelectasis from rib infarction (23, 24), exces-
sive opioid administration (25, 26), or embolization of
infarcted bone marrow to the lungs (7). The routine use of
incentive spirometry to prevent atelectasis in the setting of
acute vaso-occlusive pain crisis is effective in preventing
ACS (23). The association of higher steady-state WBC
count with ACS or pneumonia in hemoglobin SS patients
in this study is consistent with an analysis of ACS in the
Cooperative Study of Sickle Cell Disease (2).
The median steady-state TRV was 2.4 m/s in the hemo-
globin SS children and adolescents in the present study
with a history of an acute pulmonary event vs. 2.3 m/s in
those without such a history, and both of these values are
within the normal range. Nevertheless, higher TRV was
independently associated with history of acute pulmonary
events, and this is in contrast to several previous reports
failing to ﬁnd such an association in children (27–29) and
adults (30). TRV elevation is common in SCD adults dur-
ing an episode of acute chest syndrome (31). Elevated TRV
is known to be a physiologic biomarker of severity in adult
patients with SCD (30, 32, 33), but its prognostic signiﬁ-
cance in children is largely not known. We previously
reported that elevated TRV in children is associated with a
decline in exercise capacity over 2 yrs of follow-up (34).
We are unable to make a conclusion as to whether the
association between higher TRV and ACS or pneumonia in
this study is causal.
A third of patients with a history of acute pulmonary
events developed ACS during a median follow-up of
21 months in the present study. A study from the Dallas
Newborn Cohort demonstrated that ACS in the ﬁrst 3 yrs
of life signiﬁcantly increased the odds of more frequent
episodes of ACS during childhood (6). Other studies
indicate that acute chest syndrome or acute respiratory
distress syndrome in childhood may lead to sequelae
such as obstructive and/or restrictive abnormalities, ﬁbrosis,
and hypoxemia (35–37). Perhaps pulmonary injury from
previous acute pulmonary events predisposes to increased
susceptibility to recurrent events or alternatively a genetic
predisposition underlies the development of frequent ACS
episodes (38). Younger age was associated higher risk of
ACS during the follow-up period in our study. This obser-
vation is consistent with other reports that ACS is more
common in younger patients, with the highest incidence
seen in children aged 9 yrs or less and the lowest incidence
in adults (2). There is a higher risk of viral or bacterial
infections in early childhood, and pulmonary infections are
a frequent trigger of ACS (7). A decrease in the frequency
of ACS episodes in individuals with age might be
explained by acquired immunity and the preferential sur-
vival of children with a lower incidence of ACS. In gen-
eral, the physiologic abnormalities of obstructive/restrictive
defects on pulmonary function testing and hypoxemia are
likely reﬂective of an ill-deﬁned chronic lung injury that
occurs in SCD and may predispose to recurrent episodes of
ACS.
There are several limitations in our study. First, the diag-
noses of acute chest syndrome, pneumonia, and asthma were
reported by the patient or a family member and were not
conﬁrmed by chart review in all subjects. Second, associated
genomic and genetic analyses would be helpful to clarify
relevant biological mechanisms in the context of biochemical
and historical risk markers. Third, the median follow-up of
21 months was short and may have limited the identiﬁcation
of potential beneﬁcial effects of hydroxyurea treatment in
SCD patients.
In conclusion, our data indicate that acute pulmonary
events are frequent in both hemoglobin SS patients and
those with other genotypes. History of frequent severe pain
episodes was an independent predictor of a history of acute
pulmonary events among all genotypes and history of
asthma, higher TRV, and higher WBC count in patients with
hemoglobin SS. Future research should investigate whether
preventing severe pain episodes and providing optimal
treatment for asthma will decrease the incidence of acute
pulmonary events in children and adolescents with SCD.
Furthermore, our results suggest the possible importance of
stratifying ACS diagnosis according to accompanying ﬁnd-
ings such as asthma history, frequent acute pain episodes
and increased estimated systolic pulmonary artery pressure
for future studies of genotype–phenotype correlation.
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